JP2024056791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024056791A5 JP2024056791A5 JP2024016653A JP2024016653A JP2024056791A5 JP 2024056791 A5 JP2024056791 A5 JP 2024056791A5 JP 2024016653 A JP2024016653 A JP 2024016653A JP 2024016653 A JP2024016653 A JP 2024016653A JP 2024056791 A5 JP2024056791 A5 JP 2024056791A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bcma
- formulation
- percentage
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025137331A JP2025186256A (ja) | 2019-08-06 | 2025-08-20 | 生物医薬組成物及び関連する方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962883451P | 2019-08-06 | 2019-08-06 | |
| US62/883,451 | 2019-08-06 | ||
| US201962948432P | 2019-12-16 | 2019-12-16 | |
| US62/948,432 | 2019-12-16 | ||
| US202062984110P | 2020-03-02 | 2020-03-02 | |
| US62/984,110 | 2020-03-02 | ||
| JP2022506976A JP7515567B2 (ja) | 2019-08-06 | 2020-07-31 | 生物医薬組成物及び関連する方法 |
| PCT/IB2020/057267 WO2021024133A2 (en) | 2019-08-06 | 2020-07-31 | Biopharmacuetical compositions and related methods |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506976A Division JP7515567B2 (ja) | 2019-08-06 | 2020-07-31 | 生物医薬組成物及び関連する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137331A Division JP2025186256A (ja) | 2019-08-06 | 2025-08-20 | 生物医薬組成物及び関連する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024056791A JP2024056791A (ja) | 2024-04-23 |
| JP2024056791A5 true JP2024056791A5 (https=) | 2024-10-10 |
Family
ID=71994687
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506976A Active JP7515567B2 (ja) | 2019-08-06 | 2020-07-31 | 生物医薬組成物及び関連する方法 |
| JP2024016653A Pending JP2024056791A (ja) | 2019-08-06 | 2024-02-06 | 生物医薬組成物及び関連する方法 |
| JP2025137331A Pending JP2025186256A (ja) | 2019-08-06 | 2025-08-20 | 生物医薬組成物及び関連する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506976A Active JP7515567B2 (ja) | 2019-08-06 | 2020-07-31 | 生物医薬組成物及び関連する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137331A Pending JP2025186256A (ja) | 2019-08-06 | 2025-08-20 | 生物医薬組成物及び関連する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220289859A1 (https=) |
| EP (1) | EP4010372A2 (https=) |
| JP (3) | JP7515567B2 (https=) |
| KR (1) | KR20220041915A (https=) |
| CN (2) | CN114502593A (https=) |
| AU (1) | AU2020325753B2 (https=) |
| BR (1) | BR112022002236A2 (https=) |
| CA (1) | CA3146471A1 (https=) |
| CL (1) | CL2022000294A1 (https=) |
| CO (1) | CO2022002627A2 (https=) |
| IL (1) | IL290325A (https=) |
| MX (1) | MX2022001626A (https=) |
| NZ (1) | NZ784975A (https=) |
| PH (1) | PH12022550277A1 (https=) |
| TW (2) | TWI867020B (https=) |
| WO (1) | WO2021024133A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202323822A (zh) * | 2021-08-03 | 2023-06-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 生藥組合物及穩定同位素標記肽之圖譜定位方法 |
| TW202413435A (zh) * | 2022-08-05 | 2024-04-01 | 美商艾力克森製藥公司 | 融合蛋白的藥物組成物及其使用方法 |
| EP4630454A1 (en) | 2022-12-05 | 2025-10-15 | GlaxoSmithKline Intellectual Property Development Ltd | Methods of treatment using b-cell maturation antigen antagonists |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| CZ20003099A3 (cs) | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| MX391454B (es) | 2010-04-15 | 2025-03-05 | Seagen Inc | Compuesto de engarce-fármaco para conjugación a una unidad de ligando. |
| CA2833820C (en) | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| JP6694712B2 (ja) | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| CN105209076A (zh) | 2013-03-15 | 2015-12-30 | 阿布维公司 | 抗体药物偶联物(adc)纯化 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| WO2015077605A1 (en) | 2013-11-25 | 2015-05-28 | Seattle Genetics, Inc. | Preparing antibodies from cho cell cultures for conjugation |
| WO2015158671A1 (en) | 2014-04-14 | 2015-10-22 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| JP6285274B2 (ja) | 2014-04-28 | 2018-02-28 | 株式会社ブリヂストン | バイアスタイヤ及びその製造方法 |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| KR20240135036A (ko) | 2014-12-05 | 2024-09-10 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 |
| AU2015357526B2 (en) | 2014-12-05 | 2022-03-17 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| US10683369B2 (en) | 2015-08-03 | 2020-06-16 | Engmab Sàrl | Monoclonal antibodies against BCMA |
| EP3147954A1 (en) | 2015-09-22 | 2017-03-29 | Nokia Technologies Oy | Photodetector with conductive channel made from two dimensional material and its manufacturing method |
| US20200254093A1 (en) * | 2017-09-14 | 2020-08-13 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer |
| CA3079215A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
-
2020
- 2020-07-31 BR BR112022002236A patent/BR112022002236A2/pt unknown
- 2020-07-31 WO PCT/IB2020/057267 patent/WO2021024133A2/en not_active Ceased
- 2020-07-31 AU AU2020325753A patent/AU2020325753B2/en not_active Expired - Fee Related
- 2020-07-31 EP EP20753451.2A patent/EP4010372A2/en active Pending
- 2020-07-31 MX MX2022001626A patent/MX2022001626A/es unknown
- 2020-07-31 CN CN202080069015.7A patent/CN114502593A/zh active Pending
- 2020-07-31 US US17/633,115 patent/US20220289859A1/en active Pending
- 2020-07-31 KR KR1020227007373A patent/KR20220041915A/ko not_active Ceased
- 2020-07-31 PH PH1/2022/550277A patent/PH12022550277A1/en unknown
- 2020-07-31 JP JP2022506976A patent/JP7515567B2/ja active Active
- 2020-07-31 CA CA3146471A patent/CA3146471A1/en active Pending
- 2020-07-31 NZ NZ784975A patent/NZ784975A/en unknown
- 2020-07-31 CN CN202510289520.7A patent/CN120204384A/zh active Pending
- 2020-08-04 TW TW109126290A patent/TWI867020B/zh active
- 2020-08-04 TW TW111111185A patent/TW202227142A/zh unknown
-
2022
- 2022-02-03 IL IL290325A patent/IL290325A/en unknown
- 2022-02-04 CL CL2022000294A patent/CL2022000294A1/es unknown
- 2022-03-04 CO CONC2022/0002627A patent/CO2022002627A2/es unknown
-
2024
- 2024-02-06 JP JP2024016653A patent/JP2024056791A/ja active Pending
-
2025
- 2025-08-20 JP JP2025137331A patent/JP2025186256A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024056791A5 (https=) | ||
| AU2025204809A1 (en) | Humanized anti-prostate-specific membrane antigen (PSMA) antibody drug conjugates | |
| JP2025016545A5 (https=) | ||
| JP2023018157A (ja) | 親水性抗体－薬物コンジュゲート | |
| US6750329B1 (en) | Antibody delivery system for biological response modifiers | |
| JP2021519076A5 (https=) | ||
| CN1816356A (zh) | 药物缀合物组合物 | |
| JP4024852B2 (ja) | 「経皮吸収製剤」 | |
| NZ233413A (en) | Composition comprising a conjugate of an antibody directed against a tumour associated antigen and a biological response modifier | |
| JPWO2020188061A5 (https=) | ||
| JPWO2021151984A5 (https=) | ||
| JP2005506947A5 (https=) | ||
| JP2025183307A5 (https=) | ||
| JPWO2021074622A5 (https=) | ||
| JP2023159335A5 (https=) | ||
| JP2025111546A (ja) | Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質 | |
| JPWO2019191728A5 (https=) | ||
| CN113660981A (zh) | 结节性痒疹患者的皮肤病变和瘙痒的治疗 | |
| WO2019237322A1 (en) | Methods and materials for treating cancer | |
| JPWO2023083900A5 (https=) | ||
| JPWO2022078523A5 (https=) | ||
| JPH07500572A (ja) | ガン処理法 | |
| JPWO2023166322A5 (https=) | ||
| JPWO2023133388A5 (https=) | ||
| CN101277716A (zh) | 治疗癌症的抗体 |